Exploring the association of hemoglobin level and adverse events in children with cancer presenting with fever in neutropenia by Ammann, Roland A et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Exploring the association of hemoglobin level and adverse events in children
with cancer presenting with fever in neutropenia
Ammann, Roland A; Niggli, Felix K; Leibundgut, Kurt; Teuffel, Oliver; Bodmer, Nicole
Abstract: BACKGROUND In children and adolescents with fever in neutropenia (FN) during chemother-
apy for cancer, hemoglobin ￿90 g/L at presentation with FN had been associated with adverse events
(AE). This analysis explored three hypothetical pathophysiological mechanisms potentially explaining
this counterintuitive finding, and further analyzed the statistical association between hemoglobin and
AE. METHODS Two of 8 centers, reporting on 311 of 421 FN episodes in 138 of 215 patients partici-
pated in this retrospective analysis based on prospectively collected data from three databases (SPOG
2003 FN, transfusion and hematology laboratories). Associations with AE were analyzed using mixed
logistic regression. RESULTS Hemoglobin was ￿90 g/L in 141 (45%) of 311 FN episodes, specifically in
59/103 (57%) episodes with AE, and in 82/208 (39%) without (OR, 2.3; 99%CI, 1.1-4.9; P = 0.004).
In FN with AE, hemoglobin was bimodally distributed with a dip around 85 g/L. There were no sig-
nificant interactions for center, age and sex. In multivariate mixed logistic regression, AE was signif-
icantly and independently associated with leukopenia (leukocytes <0.3 G/L; OR, 3.3; 99%CI, 1.1-99;
P = 0.004), dehydration (hemoglobinPresentation/hemoglobin8-72 hours ￿1.10 in untransfused patients;
OR, 3.5; 99%CI, 1.1-11.4; P = 0.006) and non-moderate anemia (difference from 85 g/L; 1.6 per 10
g/L; 1.0-2.6; P = 0.005), but not with recent transfusion of packed red blood cells (pRBC), very recent
transfusion of pRBC or platelets, or with hemoglobin ￿90 g/L as such. CONCLUSIONS Non-moderate
anemia and dehydration were significantly and relevantly associated with the risk of AE in children with
cancer and FN. These results need validation in prospective cohorts before clinical implementation.
DOI: 10.1371/journal.pone.0101696
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-101241
Published Version
 
 
Originally published at:
Ammann, Roland A; Niggli, Felix K; Leibundgut, Kurt; Teuffel, Oliver; Bodmer, Nicole (2014). Exploring
the association of hemoglobin level and adverse events in children with cancer presenting with fever in
neutropenia. PLoS ONE, 9(7):e101696. DOI: 10.1371/journal.pone.0101696
Exploring the Association of Hemoglobin Level and
Adverse Events in Children with Cancer Presenting with
Fever in Neutropenia
Roland A. Ammann1*, Felix K. Niggli2, Kurt Leibundgut1, Oliver Teuffel1,3, Nicole Bodmer2
1Department of Pediatrics, University of Bern, Bern, Switzerland, 2Division of Oncology, Department of Pediatrics, University of Zurich, Zurich, Switzerland, 3Division of
Oncology, Medical Services of the Statutory Health Insurance Baden-Wu¨rttemberg, Tu¨bingen, Germany
Abstract
Background: In children and adolescents with fever in neutropenia (FN) during chemotherapy for cancer, hemoglobin $
90 g/L at presentation with FN had been associated with adverse events (AE). This analysis explored three hypothetical
pathophysiological mechanisms potentially explaining this counterintuitive finding, and further analyzed the statistical
association between hemoglobin and AE.
Methods: Two of 8 centers, reporting on 311 of 421 FN episodes in 138 of 215 patients participated in this retrospective
analysis based on prospectively collected data from three databases (SPOG 2003 FN, transfusion and hematology
laboratories). Associations with AE were analyzed using mixed logistic regression.
Results: Hemoglobin was$90 g/L in 141 (45%) of 311 FN episodes, specifically in 59/103 (57%) episodes with AE, and in 82/
208 (39%) without (OR, 2.3; 99%CI, 1.1–4.9; P = 0.004). In FN with AE, hemoglobin was bimodally distributed with a dip
around 85 g/L. There were no significant interactions for center, age and sex. In multivariate mixed logistic regression, AE
was significantly and independently associated with leukopenia (leukocytes ,0.3 G/L; OR, 3.3; 99%CI, 1.1–99; P= 0.004),
dehydration (hemoglobinPresentation/hemoglobin8–72 hours$1.10 in untransfused patients; OR, 3.5; 99%CI, 1.1–11.4; P= 0.006)
and non-moderate anemia (difference from 85 g/L; 1.6 per 10 g/L; 1.0–2.6; P= 0.005), but not with recent transfusion of
packed red blood cells (pRBC), very recent transfusion of pRBC or platelets, or with hemoglobin $90 g/L as such.
Conclusions: Non-moderate anemia and dehydration were significantly and relevantly associated with the risk of AE in
children with cancer and FN. These results need validation in prospective cohorts before clinical implementation.
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Introduction
Fever in neutropenia (FN) is the most frequent potentially lethal
complication of chemotherapy in pediatric patients with cancer
[1]. The prospective multicenter SPOG 2003 FN study had
investigated FN in children and adolescents with cancer. In its risk
prediction analyses, mild/no anemia at presentation with FN,
defined as hemoglobin level $90 g/L, was surprisingly found to
be associated with adverse events (AE). Specifically, a hemoglobin
level at presentation with FN (furthermore called hemoglobin)
$90 g/L significantly and independently predicted AE in general,
as well as the AE subgroups bacteremia, and serious medical
complications [2–4].
This finding seems to contradict the well-known association of
indicators of myelosuppression with the risk of AE. Besides, in the
large literature on risk prediction in pediatric FN [5], hemoglobin
had been described as a risk factor only twice, both in single-center
retrospective studies, and with conflicting results. In Switzerland,
high hemoglobin (.70 g/L) independently predicted severe
bacterial infection [6], while in Brazil, low hemoglobin
(,70 g/L) independently predicted severe infectious complications
[7].
This additional analysis of SPOG 2003 FN data aimed to
explore five hypotheses, three of them on pathophysiological and
two on statistical mechanisms potentially underlying the associa-
tion of hemoglobin level with AE in FN. The pathophysiological
mechanisms explored were (1) suppressed erythropoiesis, hemoly-
sis, or blood loss having led to transfusion of packed red blood cells
(pRBC); (2) febrile transfusion reaction despite screening and the
use of leukocyte depletion filters [8,9]; and (3) dehydration or
hemoconcentration [10,11]. The statistical mechanisms explored
were (4), non-optimal categorization of hemoglobin, which may be
non-monotonously associated with AE, by dichotomization [12];
and (5) a direct effect of high hemoglobin on the risk of AE.
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Patients and Methods
Patients, and management of fever in neutropenia
This retrospective analysis was essentially based on data from
the prospective multicenter study SPOG 2003 FN, initiated by the
Swiss Pediatric Oncology Group. This study had been open for
patient recruitment by pediatric oncology centers in Switzerland
and Germany from 2004 to 2007.
Details on eligible patients, and on management of FN have been
published [2–4]. Patients with cancer aged 1 to 18 years at
presentation with FN after non-myeloablative chemotherapy had
been eligible. Multiple episodes of FN per patient had been allowed.
Fever had been defined as axillary temperature either $38.5uC
once, or $38.0uC during $2 hours [1]. Neutropenia had been
defined as an absolute neutrophil count #0.5 G/L [1].
Hemoglobin had been determined as part of the routine blood
cell count at presentation with FN, together with blood cultures
and a physical examination. Patients had been hospitalized and
treated with empirical intravenous broad spectrum antimicrobial
therapy. The treating physician had decided on all further
diagnostic and therapeutic measures including transfusions and
follow-up determinations of hemoglobin. By institutional standard
procedures, all pRBC and single-donor apheresis platelets had
been leukocyte-depleted [8]. Few patients fulfilling restrictive
predefined low-risk criteria at reassessment after 8 to 22 hours of
inpatient-therapy and had been randomized in a low-risk
subgroup study comparing response and safety rates of oral
ciprofloxacin and amoxicillin administered in an outpatient setting
versus continued standard treatment [13].
Ethics statement
Patients, if able to judge, and their legal guardians had given
written informed consent prior to study entry. The study had been
conducted in accordance with the Declaration of Helsinki and the
Guidelines on Good Clinical Practice. The protocol had been
approved by the respective local and national ethics committees,
and registered at www.clinicaltrials.com (NCT00107081), before
starting patient accrual [2].
This retrospective analysis was approved by the Institutional
Review Board of the Inselspital Bern (registration number 13–06–
11), including waiver of renewal of informed consent. After
matching, information was anonymized for analysis.
Data bases used for this analysis
Only two of the eight SPOG 2003 FN study centers were willing
to perform the additional workload of data collection required for
participation in this additional retrospective analysis. Specifically,
this data collection required extraction of data from the database
of the transfusion facilities for data on transfusion before and after
presentation with FN, and from the database of the hematology
laboratories for results on follow-up hemoglobin determinations.
The prospectively collected data from these two databases was
added to the SPOG 2003 FN database after matching by initials,
date of birth, and date of FN. Matching was performed centrally,
and was always found to be unambiguous.
Definition of adverse events
Details on AE definition have been published [2–4]. AE
included serious medical complications due to infection [14–16],
microbiologically defined infection, and radiologically confirmed
pneumonia. Serious medical complications included death,
complication requiring intensive care unit treatment, and poten-
tially life-threatening complication as judged by the treating
physician. Microbiologically defined infections included positive
bacterial or fungal culture from a normally sterile body fluid or
compartment, and detection of a viral antigen or product of
polymerase chain reaction by a validated microbiological method.
Adverse events were reported until the day when antimicrobial
therapy had been stopped for 7 days, and severe neutropenia had
resolved, whichever occurred later.
Measures and definitions specific to the five hypotheses
A surrogate marker was defined for each of the three
pathophysiological mechanisms explored. The surrogate marker
for hypothesis (1), suppressed erythropoiesis, hemolysis, or blood
loss having led to transfusion of pRBC, was recent transfusion of
pRBC within 168 hours (7 days) before presentation with FN. The
surrogate marker for hypothesis (2), febrile transfusion reaction,
was very recent transfusion of pRBC, or single-donor apheresis
platelets, within 24 hours before presentation with FN. The
surrogate marker for hypothesis (3), dehydration or hemoconcen-
tration, was hemoglobin ratio (Hb-ratio), estimated by the ratio of
hemoglobin measured at presentation with FN, divided by
hemoglobin measured at the first follow-up blood count, if this
was performed 8 to 72 hours after presentation and only in
patients not transfused with pRBC until then).
For the two statistical mechanisms explored, (4), non-optimal
categorization of hemoglobin by dichotomization [12]; and (5) a
direct effect of high hemoglobin on the risk of AE, no specific
definitions were required.
Statistics
Median, range and interquartile range (IQR) were calculated
for non-normally distributed variables. Exact Fisher’s and Fisher-
Freeman-Halton tests, t-tests, and recursive partitioning by tree
analysis [17] were used where applicable [12]. Smoothing by 2nd
to 8th (deliberate overfitting) order linear regression on AE was
used for figures.
Univariate and multivariate mixed logistic regression, with a
random intercept per patient, was used for analysis of associations
with the binary outcomes, because multiple FN episodes per
patient were allowed [18]. In addition to known risk factors for
AE, and hypothesis-specific characteristics, interaction terms of
high hemoglobin ($90 g/L) with recent transfusion of pRBCs,
and with very recent transfusion of pRBCs/platelets, respectively,
were analyzed. Odds ratio (OR), its 99% confidence interval (CI),
and P-value were reported. For multivariate analysis, the
backward variable selection procedure was used (Pin = 0.010),
starting with the 4 respective outcome-specific characteristics
known from SPOG 2003 FN, plus one characteristic each for the
five hypotheses [12].
Two-sided tests were used throughout. Accounting for the
multiple statistical tests performed, only P-values ,0.01 were
considered significant. Correspondingly, 99% CI were calculated.
All exact analyses were performed using StatXact 10.0 (Cytel
Software Corp., Cambridge, MA, USA), and all remaining
analyses using R 2.15.1 (R Foundation for Statistical Computing,
Vienna, Austria). Specifically, for mixed logistic regression the sabre
procedure from the sabreR library was used [19].
Results
Patients and episodes of FN
Two of originally 8 SPOG 2003 FN centers participated in this
analysis, in which thus 311 (74%) of 421 FN episodes occurring in
138 (67%) of 205 patients were included. The 110 episodes from
the six centers not participating in this additional analysis had to
Hemoglobin and Adverse Events in Children with FN
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be excluded. An AE was reported in 103 (33%) of these 311 FN
episodes.
Sex, age at first FN, diagnostic group, and relapse status were
not associated with inclusion versus exclusion (Table 1). The
proportion of FN episodes with AE, however, was significantly
higher in the episodes included than in those excluded, while the
proportion of episodes with hemoglobin $90 g/L were compa-
rable. (Table 1).
Hemoglobin and adverse events
The median hemoglobin at presentation with FN was 86 g/L
(range, 44 to 151; IQR, 72 to 102). Hemoglobin was $90 g/L in
141 (45%) of the 311 FN episodes, specifically in 59 (57%) of 103
episodes with AE versus 82 (39%) of 208 without (OR, 2.3; 99%
CI, 1.1 to 4.9; p = 0.004). Hemoglobin at presentation was
bimodally distributed in FN with AE, with a dip around 85 g/L
(moderate anemia), between two peaks at severe and at mild/no
anemia. Correspondingly, the distribution of the proportions of
FN with AE versus hemoglobin was U-shaped (Figure 1).
Center was not a significant confounder for the association of
hemoglobin $90 g/L with AE (OR of interaction, 3.5; 99% CI,
0.7 to 19; p= 0.052). The same was true for sex (OR of
interaction, 1.5, 99% CI, 0.4 to 6.5, p = 0.45) and age (four
categories; all p-values for interaction .0.01) Based on these
results, all further calculations were performed without stratifica-
tion for center, sex, and age.
Characteristics from SPOG 2003 FN
In univariate analysis, three of the four characteristics indepen-
dently associated with AE in SPOG 2003 FNwere as well significantly
associated with AE in this analysis (hemoglobin $90 g/L, leukocyte
count ,0.3 G/L, platelet count ,50 G/L), while the fourth
(chemotherapy more intensive than ALL maintenance) was not.
Three pathophysiological mechanisms explored
Hypothesis (1), suppressed erythropoiesis, hemolysis, or blood
loss having led to transfusion of pRBC: A recent transfusion of
pRBC, i.e., within 7 days before presentation with FN, had been
reported in 97 (31%) of 311 FN episodes, 36 of them with AE, and
61 without. The mean hemoglobin was 91 g/L in these 97
episodes versus 85 g/L in the remaining 214 episodes (mean
difference, 6.0 g/L; 99% CI, 20.5 to 12.5 g/L; p = 0.017).
Recent transfusion of pRBC, and its interaction with hemoglobin
$90 g/L, was not significantly associated with AE (Table 2).
Hypothesis (2), febrile transfusion reaction: A very recent
transfusion of pRBC, i.e., within 24 hours before presentation with
FN, had been reported in 34 (11%) of 311 FN episodes, and a
transfusion of platelets in 39 (13%). This resulted in a total of 51
(16%) FN episodes with a very recent transfusion of pRBC and/or
platelets, 16 of them with AE, and 35 without. Very recent
transfusion of pRBC and/or platelets, and its interaction with
hemoglobin $90 g/L, were not significantly associated with AE
(Table 2).
Hypothesis (3), dehydration or hemoconcentration: Within 8 to
72 hours after presentation with FN, a follow-up hemoglobin was
Table 1. Characteristics of Patients and of FN Episodes Excluded and Included into the Analysis.
Patients and FN episodes
Characteristic SPOG 2003 FN Excludeda Includeda Pb
Patients 205 67 (33%) 138 (67%)
Sex 0.37
Female 90 26 (29%) 64 (71%)
Male 115 41 (36%) 74 (64%)
Age at first FN 0.68
,4 years 55 16 (29%) 39 (71%)
$4 and ,8 years 57 22 (39%) 35 (61%)
$8 and ,12 years 45 15 (33%) 30 (67%)
$12 years 48 14 (29%) 34 (71%)
Diagnostic group 0.25
Acute lymphoblastic leukemia 90 24 (27%) 66 (73%)
Acute myeloid leukemia 23 6 (26%) 17 (74%)
Lymphoma 16 5 (31%) 11 (69%)
Tumor of CNS 22 8 (36%) 14 (64%)
Solid tumor outside CNS 54 24 (44%) 30 (56%)
Relapse status 0.66
Non-relapsed cancer 180 60 (33%) 120 (67%)
Relapsed cancer 25 7 (28%) 18 (72%)
Episodes of FN 421 110 (26%) 311 (74%)
Episodes with adverse event 121 18 (15%) 103 (85%) ,0.001
Episodes with hemoglobin $90 g/L 189 48 (25%) 141 (75%) 0.82
FN, fever in neutropenia. aProportions of all patients/episodes in parentheses; bP-values from exact Fisher’s and Fisher-Freeman-Halton tests regarding excluded versus
included episodes or patients.
doi:10.1371/journal.pone.0101696.t001
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determined in 297 of 311 episodes (95%; median time, 20 hours;
range, 8 to 66, IQR, 14 to 35). In 78 (25%) of these episodes,
however, transfusion with pRBC had been started before
determination of follow-up hemoglobin. A Hb-ratio could thus
be calculated in 219 (70%) FN episodes (Figure 2). The median
Hb-ratio was 1.13 (range, 0.66 to 1.73; IQR, 1.07 to 1.24;
Figure 3). Recursive partitioning indicated 1.09 as significant limit
to discriminate between episodes with versus without AE. For
Figure 1. Adverse events versus hemoglobin at presentation. Frequency histogram of episodes of fever in neutropenia (FN; left vertical axis).
Proportions of FN episodes with any adverse event (AE) measured, and by 2nd and 8th order regression smoothing (right vertical axis). SMC, serious
medical complication.
doi:10.1371/journal.pone.0101696.g001
Table 2. Characteristics Associated with Adverse Events During Fever in Neutropenia.
Characteristic present in episodes Univariate analysis Multivariate analysisa
Characteristics with AE without AE OR (99%CI) P OR (99%CI) P
Independently associated in SPOG 2003 FN
Hemoglobin $90 g/L 59 of 103 (57%) 82 of 208 (39%) 2.3 (1.1 to 4.9) 0.004 Not significant -
Chemotherapy more intensive than ALL maintenance 90 of 103 (87%) 179 of 208 (86%) 1.2 (0.4 to 3.6) 0.61 Not significant -
Leukocyte count ,0.3 G/L 54 of 103 (52%) 73 of 208 (35%) 2.3 (1.1 to 4.8) 0.004 3.3 (1.1 to 9.9) 0.004
Platelet count ,50 G/L 69 of 103 (67%) 109 of 208 (52%) 1.9 (0.9 to 4.0) 0.018 Not significant -
Hypotheses tested in this analysis
H.2: Recent pRBC transfusionb 36 of 103 (35%) 61 of 208 (29%) 1.3 (0.6 to 2.7) 0.40 Not significant -
Interaction with high hemoglobin NA NA 0.8 (0.2 to 3.7) 0.73 Not tested -
H.3: Very recent pRBC/platelets transfusionc 16 of 103 (16%) 35 of 208 (17%) 0.9 (0.3 to 2.2) 0.71 Not significant -
Interaction with high hemoglobin NA NA 0.8 (0.1 to 5.5) 0.75 Not tested -
H.4: Dehydration (Hb-Ratio $1.10)a 57 of 74 (77%) 84 of 145 (58%) 3.1 (1.0 to 9.1) 0.007 3.5 (1.1 to 11.4) 0.006
Hb-Ratio as such (per 10%)a NA NA 1.4 (1.0 to 1.9) 0.020 Not tested -
H.5: Non-moderate anemia (|85 - Hb|; per 10 g/L) NA NA 1.4 (1.0 to 1.9) 0.008 1.6 (1.0 to 2.6) 0.005
H.6: High hemoglobin as such (per 10 g/L) NA NA 1.2 (1.0 to 1.4) 0.024 Not significant -
AE, adverse event; FN, fever in neutropenia; Hb, hemoglobin; NA, not applicable; pRBC, packed red blood cells. an = 219 instead of 311; bwithin 7 days; cwithin 24 hours.
doi:10.1371/journal.pone.0101696.t002
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clinical convenience, the limit of Hb-ratio defining dehydration
was set at $1.10. Dehydration was present in 141 (64%) of 219
episodes. There was a significant, essentially linear, and thus
monotonous association of Hb-ratio with AE (Table 2, Figure 3).
Two statistical mechanisms explored
Hypothesis (4), non-optimal categorization of hemoglobin by
dichotomization: Recursive partitioning of the association of
hemoglobin at presentation with AE was recalculated in these
311 FN episodes. It revealed a primary split of the regression tree
at $91 g/L, with a secondary split at $81 g/L. Moderate anemia
was associated with the lowest risk (81 to 90 g/L; 12% with AE),
while both severe anemia (,81 g/L, 31%) and mild/no anemia
($91 g/L, 44%) were associated with a higher risk (Figure 1). This
essentially U-shaped association between hemoglobin and the risk
of AE was confirmed by 2nd and higher order linear regression
smoothing. The minimum risk estimated by 2nd order linear
regression smoothing was at 75 g/L. Only using 8th or higher
order linear regression smoothing, this minimum reached the
range of 81 to 90 g/L (Figure 1). For clinical convenience, instead
of using a complex categorization of hemoglobin, the U-shaped
association for AE was integrated into a single variable, called non-
moderate anemia, defined as the absolute value of the difference of
hemoglobin from 85 g/L, |85-Hb|. There was a significant,
essentially linear, and thus monotonous association of this measure
of non-moderate anemia with AE (Figure 4, Table 2).
Hypothesis (5), direct effect of high hemoglobin on the risk of
AE: High hemoglobin, analyzed as continuous instead of
categorized variable, was not significantly associated with AE
(Table 2).
Multivariate analysis
Multivariate analysis was performed in the set of 219 FN
episodes in which Hb-ratio as measure of dehydration and
hemoconcentration was defined. Three characteristics were
significantly and independently associated with AE (74 of 219
episodes; 34%). These were leukocyte count ,0.3 G/L, dehydra-
tion defined as Hb-ratio $1.10, and non-moderate anemia
defined as |85-Hb| (Table 2).
Discussion
This analysis explored three pathophysiological and two
statistical mechanisms potentially explaining the unexpected
association of a hemoglobin level $90 g/L with an increased risk
of AE during FN in pediatric patients with cancer, which had been
found in SPOG 2003 FN. Two of these five hypothetical
mechanisms were confirmed.
Of the three pathophysiological mechanisms, dehydration or
hemoconcentration (hypothesis 3) was confirmed. It was estimated
by a Hb-ratio $1.10, which was significantly and independently
associated with AE. Hypotheses (1), suppressed erythropoiesis,
hemolysis, or blood loss having led to transfusion of pRBC), and
(2), febrile transfusion reaction, however, were falsified.
Of the two statistical mechanisms, non-optimal categorization of
hemoglobin by dichotomization (hypothesis 4) was confirmed. A
Figure 2. Course of hemoglobin used to calculate Hb-ratio. Hemoglobin at presentation, and within 72 hours later. FN, fever in neutropenia;
AE, adverse event; SMC, serious medical complication.
doi:10.1371/journal.pone.0101696.g002
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Figure 3. Adverse events versus dehydration, estimated by Hb-ratio. Frequency histogram of FN episodes (left vertical axis). Proportions of
FN episodes with any AE measured, and by 2nd and 8th order regression smoothing (right vertical axis).
doi:10.1371/journal.pone.0101696.g003
Figure 4. Adverse events versus the difference from moderate anemia. Frequency histogram of FN episodes (left vertical axis). Proportions
of FN episodes with any AE measured, and by 2nd and 8th order regression smoothing (right vertical axis).
doi:10.1371/journal.pone.0101696.g004
Hemoglobin and Adverse Events in Children with FN
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non-monotonous association of hemoglobin with the risk of AE
was found, revealing that not only mild/no anemia, but as well
severe anemia was associated with AE. This was integrated into
the notion of non-moderate anemia, estimated here by |85-Hb|
(absolute value of the difference of hemoglobin from 85 g/L).
Hypothesis (5), a direct effect of high hemoglobin on the risk of
AE, however, was falsified.
Dehydration as one of the main mechanisms confirmed here
was assessed only indirectly by estimating the surrogate marker
Hb-ratio. This relies on the follow-up determination of hemoglo-
bin before start of any pRBC transfusion. Correspondingly,
dehydration was not assessable in 30% of FN episodes. Interest-
ingly, dehydration was associated with the risk of AE indepen-
dently, i.e., in addition to, non-moderate anemia at presentation.
The pathophysiological mechanism of this association, i.e., if
dehydration is itself a cause of AE, or if it is an effect of other
causes of AE, remains unanswered here.
The hypothesized non-monotonous association of hemoglobin
with the risk of AE was confirmed here. It was found to be U-
shaped, both by graphical (Figure 1) and test-based analysis
(Table 2). Like all continuously measured variables in SPOG
2003 FN, hemoglobin at presentation had been dichotomized for
use in the prediction models based on recursive partitioning, and
respecting clinically useful limits [2]. The limit chosen, $90 g/L,
had been exactly at the main tree split found for AE (higher risk of
AE $90 g/L). A second significant split at $80 g/L (higher risk of
AE ,80 g/L) had deliberately not been used, because this would
have led to three instead of two categories. Of course, this
dichotomization reflects only the right-hand part of the U-shaped
association found here, while the left-handed part essentially reflects
myelosuppression. Correspondingly, the measure of non-moderate
anemia, integrating both parts of the U, overruled both hemoglobin
$90 g/L (right-handed part of U), and platelet count ,50 G/L
(left-handed part of U, myelosuppression) in multivariate analysis
here. The fact that leukocyte count ,0.3 G/L as a second marker
of myelosuppression, remained in the multivariate model, under-
lines the strong association of myelosuppression with the risk of AE.
When compared to published results, the U-shaped association
of hemoglobin and risk of AE found here is compatible with both
associations published until today, which seem to contradict each
other only at first sight. The association of high hemoglobin
(.70 g/L) with severe bacterial infection found in Switzerland [6]
corresponds to the right-handed part of the U, and the association
of low hemoglobin (,70 g/L) with severe infectious complications
found in Brazil [7] corresponds with its left-handed part, reflecting
additionally different transfusion strategies. Furthermore, this U-
shaped association seems to be robust, because the splits found by
recursive partitioning here were nearly identical to those found in
SPOG 2003 FN (primary split, $91 versus $90 g/L; secondary
split, $81 versus $80 g/L) [2].
Besides the 5 clinical decision rules (CDR) mentioned above [2–
4,6,7], only 3 of 13 further recently reviewed [5,20] studies
generating CDRs for pediatric FN reported non-significant
univariate associations of hemoglobin with different AE [21–23].
Since hemoglobin is routinely assessed at presentation with FN,
this may well represent underreporting of negative results. These
in turn may be due to suboptimal techniques of analysis of non-
monotonous associations by methods suited for the analysis of
monotonous associations only.
For clinical use, the replacement of the current CDR based on
the SPOG 2003 FN results [2,3] by a modified rule including
non-moderate anemia is not proposed for three reasons: First, the
aim of this analysis was not to derive a new CDR, but to explore
the mechanisms of a surprising aspect of the current CDR.
Second, replacing a partially validated CDR by non-validated
updates prevents full validation [24,25]. Third, only 8th order
linear modeling confirmed the risk of AE being lowest in the
region of 80 to 89 g/l hemoglobin, while 2nd to 7th order modeling
located this dip in lower hemoglobin regions. This indicates that
the proposed risk factor non-moderate anemia, |85-Hb|, may well
result from overfitting, thus reducing generalizability to other
patients [12].
Though this is an a posteriori analysis, it is entirely based on
prospectively collected data in a multicenter setting, with reliable
data on a large number of FN episodes in pediatric patients with a
wide spectrum of malignancies, and a wide spectrum of AE
detected. The wide spectrum of AE might be seen as a drawback,
but serious AE are frequently detected late in the course of FN
[4,26], and sometimes are preceded by apparently non-serious AE
[27]. Because of incomplete participation of former SPOG 2003
FN study centers, the proportions of FN episodes with AE, and
with SMC, were significantly higher in the episodes included than
in those excluded. This is due to the fact that both centers
participating in this analysis had recruited patients and FN
episodes without bias, while four of the remaining six centers had
preferentially recruited patients with low risk of complications [4].
The validity of the results presented here is thus not hampered. By
definition, Hb-ratio as surrogate marker of dehydration could not
be calculated in all episodes. This reduced the number of episodes
available for analyzing hypothesis 3, and for multivariate analysis,
which may have led to false negative results. More commonly used
surrogate markers for dehydration like changes in weight, urine
specific gravity, or blood urea nitrogen were not used because they
had not been systematically assessed prospectively. The use of
mixed regression techniques prevented potential drawbacks as a
result of the inclusion of multiple episodes of FN per patient [18].
In conclusion, hemoglobin at presentation with FN, specifically
both severe and mild/no anemia versus moderate anemia, was
associated significantly and relevantly with the risk of AE in
children. This non-monotonous association requires categoriza-
tion into at least three categories to become detectable. These
results need validation in other prospective cohorts before clinical
implementation, because results may be different in other patient
populations. Dehydration was found to be independently associ-
ated with AE. In future studies, it should be assessed systematically
and directly, instead of using a surrogate marker like Hb-ratio, in
order to further elucidate its value in prediction of AE in FN.
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